Infliximab biosimilar - Merck & Co/Samsung Bioepis

Drug Profile

Infliximab biosimilar - Merck & Co/Samsung Bioepis

Alternative Names: Flixabi; Infliximab - Samsung Bioepis; RENFLEXIS; SB 2

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator Samsung Bioepis
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 24 Apr 2017 Registered for Ankylosing spondylitis in Australia (IV) before April 2017
  • 24 Apr 2017 Registered for Ankylosing spondylitis in USA (IV)
  • 24 Apr 2017 Registered for Crohn's disease in Australia (IV) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top